PacBio Sequencing for Human Applications to be Featured at

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
PacBio Sequencing for Human Applications to be Featured at ASHG Annual Meeting

MENLO PARK, Calif., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc., (Nasdaq: PACB ) provider of the PacBio ® RS II DNA Sequencing System, today announced that its Single Molecule, Real-Time (SMRT ® ) Sequencing technology will be featured in a number of presentations at the 2014 American Society of Human Genetics Annual Meeting taking place October 18-22 at the San Diego Convention Center.

"We've seen great momentum over the last year with customers and collaborators using our SMRT Sequencing technology for human genetic research and believe we are in a better position than ever to showcase our products going into this important annual meeting," said Kevin Corcoran, Senior Vice President of Market Development for Pacific Biosciences. "Researchers are increasingly realizing SMRT Sequencing is not only a method of choice for human genetic studies, it is a necessary tool when highly accurate and complete coverage is required. We recently announced the purchase of multiple PacBio RS II instruments by Macrogen and Craig Venter's Human Longevity Institute, and look forward to more organizations like these that are involved in large-scale human population genetic projects adopting our technology."

Attendees at the meeting can learn more about SMRT Sequencing at the following presentations:

Podium Presentations:

Sunday, October 19

11:30 a.m.

  • Discovery and Impact of Balanced Inversion Polymorphisms
    Jan Korbel, European Molecular Biology Laboratory (EMBL)

Tuesday, October 21

8:00 a.m.

  • Completion of the 1000 Genomes Project: Results, Lessons Learned and Open Questions
    Goncalo R. Abecasis, University of Michigan School of Public Health

11:45 a.m.

  • High-throughput Determination of Long INterspersed Element-1 Integration Preferences in the Human Genome
    Diane A. Flasch, University of Michigan Medical School

5:45 p.m.

  • Increased Complexity of the Human Genome Revealed by Single-Molecule Sequencing
    Mark Chaisson, University of Washington

Workshop

Pacific Biosciences will host a workshop: "A New Look at the Human Genome – Novel Insights with Long-Read PacBio Sequencing," on Tuesday, October 21, 12:30 p.m. – 2:00 p.m. Speakers and topics include:

  • Increased Complexity of the Human Genome Revealed by Single-Molecule Sequencing
    Evan Eichler, Ph.D., University of Washington
  • Defining a Personal, Allele-Specific, and Single-Molecule Long-Read Transcriptome
    Hagen Tilgner, Ph.D., Stanford University
  • Long-Read Multiplexed Amplicon Sequencing: Applications for Epigenetics and Pharmacogenetics
    Stuart Scott, Ph.D., Icahn School of Medicine at Mount Sinai

Attendees can also visit members of the PacBio staff at booth #931, and view numerous poster presentations about SMRT Sequencing on topics such as HLA genotyping, resolving 'dark matter' in human genomes, transcriptome sequencing and DNA methylation analysis, in the Exhibit Hall.

A number of recent publications and presentations have highlighted the advantages of using long-read SMRT Sequencing data to extend the view of human genetic variation. The long sequence reads provided by the PacBio RS II are complementary to short reads from high-throughput machines because they enable human genome researchers to, for example, sequence complex genomic regions, resolve structural variation, phase haplotypes, improve the utility and mapping ability of reference genomes, fill gaps, and validate variant calls. This provides the most comprehensive view possible of the human genome.

For more information or to register for the PacBio workshop visit: http://programs.pacificbiosciences.com/l/1652...-22/2wst89

About the PacBio RS II and SMRT Sequencing

Pacific Biosciences' SMRT Sequencing technology achieves the industry's longest read lengths, highest consensus accuracy, and the least degree of bias. These characteristics, combined with the ability to detect many types of DNA base modifications (e.g., methylation) as part of the sequencing process, make the PacBio RS II an essential tool for many scientists studying genetic and genomic variation. The PacBio platform provides a sequencing solution that can address a growing number of complex medical, agricultural, and industrial problems.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (Nasdaq: PACB ) offers the PacBio RS II DNA Sequencing System to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT) technology, the company's products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate, and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems. More information is available at www.pacb.com

Forward Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, future uses of the Company's products, the Company's prospects and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company's control and could materially affect actual results. Factors that could materially affect actual results can be found in our filings with the Securities and Exchange Commission, including our most recent reports on Forms 10-K and 10-Q, and include those listed under the caption "Risk Factors." The Company undertakes no obligation to update forward-looking statements.

For Pacific Biosciences: Media: Nicole Litchfield 415.793.6468 Investors: Trevin Rard 650.521.8450

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 39

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 97

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 97

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 196

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 64

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 247

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 119

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 93

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading

Top 5 Most Recently Viewed Articles

Ethyl Alcohol Market Poised for Growth Amid AI Innovations

Updated Category News Views 195

Ethyl Alcohol Market Growth Fueled by AI Innovations The ethyl alcohol market is on the brink of significant growth as industries worldwide evolve. Recent trends suggest a promising expansion, with an expected increase of USD 16.94 billion from 2024 to 2028, based on insightful reports. This upward trajectory will stem from several key factors, such as an ample supply of...

Continue Reading
Meghan's Exciting Gourmet Brand Launch: A New Era Begins

Updated Category News Views 344

Meghan, Duchess of Sussex, Launches Gourmet Brand In a fresh and exciting venture, Meghan, Duchess of Sussex, proudly presents her new brand, As Ever. This lifestyle brand focuses on offering beautifully crafted gourmet products meant to enhance daily living. Known for her commitment to quality and authenticity, Meghan has partnered with skilled artisans to ensure each...

Continue Reading
Osisko Development Completes US$24.2 Million Private Placement

Updated Category News Views 64

Osisko Development Corp. hit a key funding milestone back in 2024 when it pulled together around US$24.2 million through a non-brokered private placement. This wasn’t just another run-of-the-mill financing—traders were watching closely as Osisko’s ambitious plans for the gold sector began to take shape. Private Placement Breakdown: What You Need to Know The first...

Continue Reading
Tesla's Stock Adjustment: Analyst Insights on AI and Valuation

Updated Category News Views 261

Tesla Faces New Analyst Ratings Amid Market Dynamics Tesla Inc. shares have seen a downward shift recently due to a change in rating from a prominent investment bank. Following Morgan Stanley's latest assessment, the stock's rating transitioned from Overweight to Equal-Weight. This reevaluation stems from concerns surrounding valuation, as new lead analyst Andrew Percoco...

Continue Reading
FTAI Aviation Ltd. Announces Strong Q3 2025 Performance Review

Updated Category News Views 328

FTAI Aviation Ltd. Financial Highlights for Q3 2025 FTAI Aviation Ltd. (NASDAQ: FTAI) revealed its financial results for the third quarter of 2025, demonstrating significant growth and profitability during this period. The company's net income attributable to shareholders reached a remarkable $114 million, which translates to an earnings per share (EPS) of $1.11, marking...

Continue Reading